Adverse effects associated with canagliflozin in initial safety trials include increased incidence of genitourinary infections, increased serum creatinine, hypoglycemia when administered with sulfonylureas or insulin, and hyperkalemia in patients with chronic kidney disease [10]. This evidence concerns the gene INS and Hypoglycemia.